Difference between revisions of "Goserelin (Zoladex)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
|||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 19: | Line 19: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
''The approval of this drug pre-dates the EMA.'' | ''The approval of this drug pre-dates the EMA.'' | ||
| + | *1987-05-12: EURD | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
| − | *2014-03-17: | + | *2014-03-17: New additional indication for the treatment of premenopausal [[breast cancer]]. |
==Also known as== | ==Also known as== | ||
| Line 37: | Line 38: | ||
[[Category:FDA approved in 1989]] | [[Category:FDA approved in 1989]] | ||
| + | [[Category:EMA approved in 1987]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 01:01, 29 June 2024
General information
Class/mechanism: Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesis[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Patient counseling information can be found in the package insert[1]
- Goserelin (Zoladex) patient drug information (Chemocare)[3]
- Goserelin (Zoladex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1989-12-29: Initial FDA approval for palliative treatment of advanced carcinoma of the prostate. (Based on Pilepich et al. 1995)
History of changes in EMA indication
The approval of this drug pre-dates the EMA.
- 1987-05-12: EURD
History of changes in PMDA indication
- 2014-03-17: New additional indication for the treatment of premenopausal breast cancer.
Also known as
- Generic name: goserelin acetate
- Brand names: Novgos, Zoladex